IL158361A0 - Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3 one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated therewith - Google Patents

Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3 one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated therewith

Info

Publication number
IL158361A0
IL158361A0 IL15836102A IL15836102A IL158361A0 IL 158361 A0 IL158361 A0 IL 158361A0 IL 15836102 A IL15836102 A IL 15836102A IL 15836102 A IL15836102 A IL 15836102A IL 158361 A0 IL158361 A0 IL 158361A0
Authority
IL
Israel
Prior art keywords
alpha
treatment
alkyl
hydrogen
epoxyandrostan
Prior art date
Application number
IL15836102A
Other languages
English (en)
Original Assignee
Stegram Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9912534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158361(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stegram Pharmaceuticals Ltd filed Critical Stegram Pharmaceuticals Ltd
Publication of IL158361A0 publication Critical patent/IL158361A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
IL15836102A 2001-04-09 2002-04-09 Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3 one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated therewith IL158361A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0108865A GB2375958B (en) 2001-04-09 2001-04-09 The use of steroids to lower the levels of cortisol
PCT/GB2002/001653 WO2002080930A1 (en) 2001-04-09 2002-04-09 Intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with abnormal concentrations of such hormones in man and animals

Publications (1)

Publication Number Publication Date
IL158361A0 true IL158361A0 (en) 2004-05-12

Family

ID=9912534

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15836102A IL158361A0 (en) 2001-04-09 2002-04-09 Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3 one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated therewith
IL158361A IL158361A (en) 2001-04-09 2003-10-09 Annals of @@@ α-cyano-@ α @ E – α epoxyandrostane - @@ β– and @@ - van @@ for continuous treatment of horse laminitis, Cushing's syndrome and Cushing's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158361A IL158361A (en) 2001-04-09 2003-10-09 Annals of @@@ α-cyano-@ α @ E – α epoxyandrostane - @@ β– and @@ - van @@ for continuous treatment of horse laminitis, Cushing's syndrome and Cushing's disease

Country Status (18)

Country Link
US (1) US9283235B2 (xx)
EP (1) EP1385527B2 (xx)
JP (1) JP5006502B2 (xx)
AT (1) ATE363285T1 (xx)
AU (1) AU2002242906B2 (xx)
CA (1) CA2443633C (xx)
CY (1) CY1106818T1 (xx)
DE (1) DE60220400T9 (xx)
DK (1) DK1385527T4 (xx)
ES (1) ES2287252T5 (xx)
GB (1) GB2375958B (xx)
IL (2) IL158361A0 (xx)
MX (1) MXPA03009236A (xx)
NZ (1) NZ529141A (xx)
PT (1) PT1385527E (xx)
SI (1) SI1385527T2 (xx)
WO (1) WO2002080930A1 (xx)
ZA (1) ZA200308567B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468282A3 (en) 2005-07-12 2012-09-12 DMI Biosciences, Inc. Methods and products for treatment of diseases
FR2931678B1 (fr) * 2008-05-27 2010-10-01 Cll Pharma Utilisation du trilistane pour le traitement de la depression
CA2742964C (en) * 2008-11-07 2020-07-07 University Of Sheffield Medicament and method of diagnosis
PL2425839T3 (pl) 2009-06-22 2015-03-31 Ampio Pharmaceuticals Inc Sposób leczenia chorób
SG10201403388SA (en) * 2009-06-22 2014-10-30 Ampio Pharmaceuticals Inc Methods and products for treatment of diseases
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
JP2016503794A (ja) 2012-12-19 2016-02-08 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾患の治療のための方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1123770A (en) * 1966-11-15 1968-08-14 Sterling Drug Inc 2-cyano-3-oxo-steroids
US3296255A (en) * 1963-11-29 1967-01-03 Sterling Drug Inc 2-cyano steroids
US3296295A (en) * 1964-05-22 1967-01-03 Squibb & Sons Inc Norsteroids
US4029776A (en) * 1975-12-19 1977-06-14 Sterling Drug Inc. Therapeutic composition and method of use thereof
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4062954A (en) * 1976-12-27 1977-12-13 Sterling Drug Inc. Process for using a steroid compound
US4160027A (en) * 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
US4331663A (en) * 1981-06-19 1982-05-25 Sterling Drug Inc. 4α,5α-Epoxy-3,20-dioxopregnane-2α,16α-dicarbonitrile and intermediates and process for preparation, method of use and compositions thereof
JPS5995300A (ja) * 1982-11-02 1984-06-01 スタ−リング・ドラッグ・インコ−ポレ−テッド コントロ−ルされた粒度の２−シアノ−４，５−エポキシ−３−オキソ−ステロイド類およびそれらの組成物
JPS5971578U (ja) * 1982-11-04 1984-05-15 アンプ　インコ−ポレ−テツド 電気コネクタ組立体
GB8328929D0 (en) * 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
GB2155018B (en) * 1984-02-25 1988-04-07 Sterwin Ag 2x-cyano-4d,5x-epoxy-androstane -3,17-dione
GB8404980D0 (en) * 1984-02-25 1984-03-28 Sterwin Ag Steroid compound
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4755595A (en) * 1985-11-01 1988-07-05 Sterling Drug Inc. Enhanced production of 4,5-unsaturated steroids utilizing methanol solvation
US5795881A (en) * 1987-06-16 1998-08-18 Schering Aktiengesellschaft Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
US4857333A (en) * 1988-05-12 1989-08-15 Harold Robert G Food product for administering medication to animals
DE69022722T2 (de) * 1989-03-10 1996-05-02 Endorecherche Inc Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
GB2345851B (en) * 2000-01-18 2004-05-26 Gavin Paul Vinson A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
PL360153A1 (en) 2000-05-15 2004-09-06 Pharmacia & Upjohn S.P.A. Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US20030050291A1 (en) * 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors

Also Published As

Publication number Publication date
SI1385527T2 (sl) 2012-03-30
CY1106818T1 (el) 2012-05-23
IL158361A (en) 2013-07-31
ATE363285T1 (de) 2007-06-15
PT1385527E (pt) 2007-08-21
CA2443633C (en) 2010-06-22
DE60220400T3 (de) 2012-03-22
CA2443633A1 (en) 2002-10-17
EP1385527B2 (en) 2011-11-23
JP2004529142A (ja) 2004-09-24
DE60220400T9 (de) 2012-08-30
GB0108865D0 (en) 2001-05-30
DE60220400D1 (de) 2007-07-12
DE60220400T2 (de) 2008-01-31
GB2375958A (en) 2002-12-04
NZ529141A (en) 2005-09-30
DK1385527T4 (da) 2012-01-16
WO2002080930A1 (en) 2002-10-17
DK1385527T3 (da) 2007-10-29
MXPA03009236A (es) 2004-11-12
ES2287252T5 (es) 2012-03-26
GB2375958B (en) 2005-03-02
AU2002242906B2 (en) 2009-07-02
ZA200308567B (en) 2006-04-29
SI1385527T1 (sl) 2007-10-31
ES2287252T3 (es) 2007-12-16
EP1385527B1 (en) 2007-05-30
US9283235B2 (en) 2016-03-15
US20040204392A1 (en) 2004-10-14
EP1385527A1 (en) 2004-02-04
JP5006502B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
ATE347365T1 (de) Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
HRP20050781B1 (hr) Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu
CY1106818T1 (el) Χρηση παραγωγων 2-αλφα-κυανο-4-αλφα, 5-αλφα-εποξυανδροσταν-17-βητα -ολ-3-ονης για μειωση επιπεδων κορτιζολης ορου και για τη θεραπεια κλινικων καταστασεων που σχετιζονται με αυτη
DE60129550D1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
BÉLANGER et al. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer
AU2001249661B2 (en) Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
ATE350041T1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
KR950700923A (ko) 암치료에 유용한 17-치환된 스테로이드(17-substituted steroids useful in cancer treatment)
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
AR018660A1 (es) Una composicion farmaceutica que comprende androst-5-en-3beta,17beta-diol o una prodroga del mismo; un kit y metodos terapeuticos que utilizan dicha composicion y un parche transdermico.
KR950701527A (ko) 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
WO2006003013B1 (de) NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1
JPH0132235B2 (xx)
Celasco et al. Biological profile of cortexolone 17a-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
HU204065B (en) Process for producing 10(2-propinyl)-19-norandrost-5-ene-3beta,17beta-diol and pharmaceutical compositins comprising such compound
US7939517B2 (en) 1,4,6-androstatriene-3,17-dione (“ATD”) for therapeutic uses
CA2395481A1 (en) Hormone receptor modulation
WO2004093852A3 (en) Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
Kincl et al. Influence of progestational agents on the genetic female foetus of orally treated pregnant rats
ATE405274T1 (de) Heilmittel für erkrankungen der retina und der aderhaut die als aktive bestandteile steroide enthalten
GB1427645A (en) Pregnane derivative its preparation and compositions thereof
RU2006126632A (ru) Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль
ES336691A1 (es) Procedimiento para la preparacion de 10alfa-esteroides.
GB928714A (en) Process for the preparation of 4-hydroxy-3-keto-í¸-steroids